Evidence map›Paper›PMID 41112240›Full record

ArticleFrontiers in immunology2025

Toll-like receptor activation and gene delivery efficiency in canine dendritic cells: a model for comparative oncology.

Sonia Capellero, Raffaella De Maria, Lisa Adele Piras, Laura Marconato, Lorenza Parisi, Eugenio Mazzone, Caterina Marchiò, Enrico Berrino, Sara Erika Bellomo, Anna Sapino and 4 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sonia Capellero *Department of Veterinary Sciences, University of Turin, Grugliasco, Italy.
Raffaella De Maria *Department of Veterinary Sciences, University of Turin, Grugliasco, Italy.
Lisa Adele PirasDepartment of Veterinary Sciences, University of Turin, Grugliasco, Italy.
Laura MarconatoDepartment of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
Lorenza ParisiDepartment of Veterinary Sciences, University of Turin, Grugliasco, Italy.
Eugenio MazzoneDepartment of Veterinary Sciences, University of Turin, Grugliasco, Italy.
Caterina MarchiòDepartment of Medical Sciences, University of Turin, Torino, Italy.
Enrico BerrinoCandiolo Cancer Institute, FPO-IRCCS, Candiolo, TO, Italy.
Sara Erika BellomoCandiolo Cancer Institute, FPO-IRCCS, Candiolo, TO, Italy.
Anna SapinoDepartment of Medical Sciences, University of Turin, Torino, Italy.
Giovanni Paolo StolaDepartment of Mechanical and Aerospace Engineering, Politecnico di Torino, Torino, Italy.
Valeria ChionoDepartment of Mechanical and Aerospace Engineering, Politecnico di Torino, Torino, Italy.
Letizia NicolettiDepartment of Mechanical and Aerospace Engineering, Politecnico di Torino, Torino, Italy.
Luca AresuDepartment of Veterinary Sciences, University of Turin, Grugliasco, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Dendritic cells (DCs) are pivotal antigen-presenting cells capable of bridging innate and adaptive immunity, making them promising candidates for cancer immunotherapy. While canine mature DCs (cmDCs) have been successfully generated from circulating mononuclear cells (CMCs) in healthy dogs, their derivation and immunomodulatory capacity in tumor-bearing dogs (TbDs) remain poorly characterized. Methods: In this study, we evaluated the efficiency of cmDC generation from peripheral blood of both healthy donors (HDs) and TbDs and investigated their functional responses to Toll-like receptor (TLR) agonists and mRNA-based genetic modification. Results: CD14 Conclusions: Our findings demonstrate that cmDCs derived from both HDs and TbDs are phenotypically and functionally competent and can be efficiently transfected using a non-viral mRNA delivery system. This strategy offers a viable platform for the development of personalized, DC-based cancer vaccines in canine patients.

Indexed as

Gene Transfer TechniquesLipopolysaccharide ReceptorsNeoplasmsAnimalsCell DifferentiationCells, CulturedCytokinesDendritic CellsDogsGenetic TherapyToll-Like ReceptorsCytokinesLipopolysaccharide ReceptorsToll-Like Receptorsdendritic cellslipoplexesmRNA transfectiontoll-like receptortumor-bearing dogs

Identifiers

PMID41112240
PMCPMC12531200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.